Mar 23 2010
Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on
the TASE (TASE:CFBI) and developing anti- inflammatory and anti-cancer
drugs, announced today the filing of a patent application, in
conjunction with the United Stated National Institutes of Health (NIH),
for the treatment of Uveitis with its A3 adenosine receptor ligands.
Uveitis is the third ophthalmology indication being pursued by Can-Fite,
in addition to Dry Eye Syndrome and Glaucoma. Can-Fite successfully
concluded a Phase II clinical study in patients with dry eye syndrome
recently, and is currently conducting a Phase II clinical trial in
patients with Glaucoma or Ocular Hypertension.
“the
current standard of care for patients with uveitis is steroids and
systemic immunosuppressive therapy. The lack of specific drugs for the
treatment of this condition creates a need for novel targeted therapies
such as the products Can-Fite develops.”
Can-Fite and the National Eye Institute of the NIH, which
collaborate under a Material-Transfer Cooperative Research and
Development Agreement (M-CRADA), conducted animal studies which
demonstrated the efficacy of Can-Fite’s lead molecule, CF101, in the
treatment of experimental autoimmune uveitis. The submitted patent
application protects the use of A3 adenosine receptor agonists for the
treatment of Uveitis. Can-Fite is a leading company in the development
of A3 adenosine receptors agonists for the treatment of human disease.
Uveitis is a chronic inflammatory disease that involves the
internal parts of the eye. This disease can lead to severe pain and
partial or complete vision loss. In some cases, uveitis is associated
with other autoimmune diseases such as rheumatoid arthritis and Behcet's
disease.
Prof. Pnina Fishman, CEO of Can-Fite, said today that "the
current standard of care for patients with uveitis is steroids and
systemic immunosuppressive therapy. The lack of specific drugs for the
treatment of this condition creates a need for novel targeted therapies
such as the products Can-Fite develops."
Source Can-Fite BioPharma Ltd
CAR T cell therapy breakthroughs bring new hope for treating solid tumors